Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: EU & WHO Urge Higher Vaccine Uptake, UK Extends Vaccination To All 16/17 Year Olds

Executive Summary

The UK REACT study shows that COVID-19 infection rates are three times lower for people who have completed their vaccination course, but the US CDC has warned that those who are fully vaccinated can still transmit the Delta variant. In the EU, the European Medicines Agency is to resume some face-to-face meetings.

You may also be interested in...



UK Venture Plans ‘Smart’ Randomized Trials To Speed Access To New Drugs

A newly launched UK venture is planning to use smart randomized clinical trial design in collaboration with industry, patient, academic and clinical partners to develop better treatments for a range of life-threatening diseases.

Australian Regulator Proposes Fee Increase To Offset Rising Costs

A growing role in dealing with medicines shortages, COVID-19-related pressures and the costs of relocating to new premises are among the factors behind the TGA’s proposal to raise the fees it charges pharma firms for its regulatory services.

Coronavirus Notebook: Australia OKs Paxlovid, Lagevrio & Nuvaxovid, New Sputnik Data Show ‘Strong Protection’ Against Omicron

International regulators have broadened their discussions on the possible use of bivalent and multivalent vaccines, and the French presidency of the Council of the EU has called for “international solidarity” on vaccine provision.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144755

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel